Prostate Bed Radiotherapy – When and What?

Česká verze

Authors: J. Šefrová ¹; K. Odrážka ^2,3,4,5; P. Paluska ¹; M. Broďák ⁶; L. Rousková ¹
Authors place of work: Klinika onkologie a radioterapie, FN Hradec Králové ¹; Multiscan s. r. o., Oddělení klinické a radiační onkologie, Pardubická krajská nemocnice, a. s., Pardubice ²; Onkologická klinika 1. LF UK a VFN, Praha ³; Radioterapeutická a onkologická klinika 3. LF UK, Praha ⁴; Katedra radiační onkologie, Institut postgraduálního vzdělávání ve zdravotnictví, Praha ⁵; Urologická klinika, FN Hradec Králové ⁶
Published in the journal: Klin Onkol 2010; 23(2): 78-85
Category: Přehledy

Summary

Backgrounds:
Recently, prostate bed irradiation has, due to the results of randomized trials which confirmed its benefit in adjuvant treatment, become the standard treatment for patients with risk factors after radical prostatectomy. It is also irreplaceable in the treatment of biochemical progression caused by local recurrence. In most cases, the tumour is not visible on planning CT, so it is necessary to use all available information to define the target volume to treat all the sites where the recurrence could be present. Design: The aim of this review is to provide a compendium of radiotherapy after radical prostatectomy, its indications and especially the localization of recurrences, which implicates the clinical target volume definitions.

Conclusion:
The treatment of prostate cancer requires close co-operation between urologists and radiation oncologists, especially now when the indication of radiotherapy includes patients with risk factors after radical prostatectomy where adjuvant treatment should be performed early after surgery. It is of the utmost importance to precisely define the target volume for radiotherapy to fully prevent local recurrence without unnecessary complications for the patient.

Key words:
prostate cancer – radiotherapy – radiotherapy planning

Zdroje

1. Pasquier D, Ballereau C. Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review. Int J Radiat Oncol Biol Phys 2008; 72(4): 972– 979.

2. Ganswindt U, Stenzl A, Bamberg M et al. Adjuvant radiotherapy for patients with locally advanced prostate cancer‑ a new standard? Eur Urol 2008; 54(3): 528– 542.

3. Bott SR, Freeman AA, Stenning S et al. Links Radical prostatectomy: pathology findings in 1001 cases compared with other major series and over time. BJU Int 2005; 95(1): 34– 39.

4. Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281(17): 1591– 1597.

5. Swanson GP, Hussey MA, Tangen CM et al. SWOG 8794, Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 2007; 25(16): 2225– 2229.

6. Epstein JI, Carmichael MJ, Pizov G et al. Links Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long‑term followup. J Urol 1993; 150(1): 135– 141.

7. Stephenson AJ, Shariat SF, Zelefsky MJ et. al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004; 291(11): 1325– 1332.

8. Stephenson AJ, Scardino PT, Eastham JA et al. Postoperative nomogram predicting the 10‑year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005; 23(28): 7005– 7012.

9. Jhaveri FM, Klein EA. How to explore the patient with a rising PSA after radical prostatectomy: defining local versus systemic failure. Semin Urol Oncol 1999; 17(3): 130– 134.

10. Scattoni V, Montorsi F, Picchio M et al. Diagnosis of local recurrence after radical prostatectomy. BJU Int 2004; 93(5): 680– 688.

11. Obek C, Neulander E, Sadek S et al. Is there a role for digital rectal examination in the followup of patients after radical prostatectomy? J Urol 1999; 162(3 Pt 1): 762– 764.

12. Pound CR, Christens‑Barry OW, Gurganus RT et al. Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. J Urol 1999; 162(4): 1337– 1340.

13. Leventis AK, Shariat SF, Slawin KM. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 2001; 219(2): 432– 943.

14. Fowler JE Jr, Brooks J, Pandey P et al. Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. J Urol 1995; 153(3 Pt 2): 1011– 1014.

15. Scattoni V, Roscigno M, Raber M et al. Multiple vesico‑ urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol 2003; 44(4): 407– 414.

16. Connolly JA, Shinohara K, Presti JC Jr et al. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate‑ specific antigen and surgical margins. Urology 1996; 47(2): 225– 231.

17. Kane CJ, Amling CL, Johnstone PA et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 2003; 61(3): 607– 611.

18. Seltzer MA, Barbaric Z, Belldegrun A et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 1999; 162(4): 1322– 1328.

19. Raj GV, Partin AW, Polascik TJ. Clinical utility of indium 111- capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 2002; 94(4): 987– 996.

20. Kotzerke J, Prang J, Neumaier B et al. Experience with carbon‑ 11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000; 27(9): 1415– 1419.

21. Rinnab L, Simon J, Hautmann RE et al. [(11)C]choline PET/ CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol 2009; 27(5): 619– 625.

22. Reske SN, Blumstein NM, Glatting G. [11C]choline PET/ CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008; 35(1): 9– 17.

23. Sella T, Schwartz LH, Swindle PW et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004; 231(2): 379– 385.

24. Silverman JM, Krebs TL. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol 1997; 168(2): 379– 385.

25. Cirillo S, Petracchini M, Scotti L et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2– weighted and contrast‑ enhanced imaging. Eur Radiol 2009; 19(3): 761– 769.

26. Tiguert R, Forman JD, Hussain M et al. Radiation therapy for a rising PSA level after radical prostatectomy. Semin Urol Oncol 1999; 17(3): 141– 147.

27. Al‑ Mamgani A, van Putten WL, Heemsbergen WD et al. Dutch multicenter dose‑escalation trial of radiotherapy for localized prostate cancer. Int J R adiat Oncol Biol Phys 2008; 72(4): 980– 988.

28. Peeters ST, Heemsbergen WD, Koper PC et al. Dose‑response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J C lin Oncol 2006; 24(13): 1990– 1996.

29. Zietman AL, DeSilvio ML, Slater JD et al. Comparison of conventional‑dose vs high‑dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005; 294(10): 1233– 1239.

30. Dearnaley DP, Sydes MR, Graham JD et al. Escalated‑dose versus standard‑dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8(6): 475– 487.

31. Zelefsky MJ, Leibel SA, Gaudin PB et al. Dose escalation with three‑ dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998; 41(3): 491– 500.

32. Zelefsky MJ, Yamada Y, Fuks Z et al. Long‑term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases‑free survival outcomes. Int J Radiat Oncol Biol Phys 2008; 71(4): 1028– 1033.

33. Valicenti RK, Gomella LG, Ismail M et al. Durable efficacy of early postoperative radiation therapy for high‑risk pT3N0 prostate cancer: the importance of radiation dose. Urology 1998; 52(6): 1034– 1040.

34. King CR, Spiotto MT. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys 2008; 71(1): 23– 27.

35. Cox JD, Gallagher MJ, Hammond EH et al. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re‑biopsy after radiation and for radiation therapy with rising prostate‑ specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 1999; 17(4): 1155.

36. King CR, Kapp DS. Radiotherapy after prostatectomy: is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys 2008; 71(2): 346– 350.

37. Thompson IM, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long‑term followup of a randomized clinical trial. J Urol 2009; 181(3): 956– 962.

38. Wiegel T, Bottke D, Steiner U et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate‑ specific antigen: ARO 96– 02/ AUO AP 09/ 95. J Clin Oncol 2009; 27(18): 2924– 2930.

39. Van der Kwast TH, Bolla M, Van Poppel H et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007; 25(27): 4178– 4186.

40. Trock BJ, Han M, Freedland SJ et al. Prostate cancer‑ specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299(23): 2760– 2769.

41. Michalski JM, Lawton C, El Naqa I et al. Development of RTOG Consensus Guidelines for the Definition of the Clinical Target Volume for Postoperative Conformal Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2010; 76(2): 361– 368.

42. Poortmans P, Bossi A, Vandeputte K et al. EORTC Radiation Oncology Group Guidelines for target volume definition in post‑operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol 2007; 84(2): 121– 127.

43. Wiltshire KL, Brock KK, Haider MA et al. Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy. Int J Radiat Oncol Biol Phys 2007; 69(4): 1090– 1099.

44. Sidhom MA, Kneebone AB, Lehman M et al. Post‑prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito- Urinary Group. Radiother Oncol 2008; 88(1): 10– 19.